GH Research (NASDAQ:GHRS) Earns Outperform Rating from Analysts at Royal Bank of Canada

Royal Bank of Canada assumed coverage on shares of GH Research (NASDAQ:GHRS - Free Report) in a report issued on Friday, MarketBeat.com reports. The brokerage issued an outperform rating and a $31.00 price target on the stock.

Several other analysts have also recently issued reports on GHRS. Cantor Fitzgerald assumed coverage on GH Research in a report on Thursday, February 13th. They set an "overweight" rating and a $14.00 price objective on the stock. Stifel Nicolaus upped their price target on shares of GH Research from $18.00 to $32.00 and gave the company a "buy" rating in a research note on Thursday, February 27th. HC Wainwright reiterated a "buy" rating and set a $40.00 price objective on shares of GH Research in a research report on Monday, January 27th. Finally, Canaccord Genuity Group lowered their price objective on shares of GH Research from $31.00 to $28.00 and set a "buy" rating for the company in a research report on Monday, November 18th. Six investment analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock currently has a consensus rating of "Buy" and a consensus target price of $30.67.

GH Research Stock Performance

Shares of GH Research stock traded down $0.05 on Friday, hitting $10.50. 268,703 shares of the company traded hands, compared to its average volume of 161,871. The stock has a market capitalization of $546.29 million, a P/E ratio of -13.29 and a beta of 0.94. The business has a 50-day simple moving average of $10.80 and a 200 day simple moving average of $9.18. GH Research has a 52 week low of $6.00 and a 52 week high of $20.50.

Remove Ads

GH Research (NASDAQ:GHRS - Get Free Report) last released its quarterly earnings data on Thursday, February 27th. The company reported ($0.17) EPS for the quarter, beating the consensus estimate of ($0.23) by $0.06. Research analysts expect that GH Research will post -0.8 earnings per share for the current year.

Institutional Investors Weigh In On GH Research

Several institutional investors have recently made changes to their positions in the company. Geode Capital Management LLC lifted its holdings in shares of GH Research by 4.5% in the 4th quarter. Geode Capital Management LLC now owns 72,513 shares of the company's stock worth $508,000 after acquiring an additional 3,092 shares during the last quarter. AdvisorShares Investments LLC increased its stake in GH Research by 15.4% in the 4th quarter. AdvisorShares Investments LLC now owns 36,011 shares of the company's stock worth $252,000 after buying an additional 4,806 shares during the period. BNP Paribas Financial Markets purchased a new position in GH Research in the 4th quarter worth about $44,000. Northern Trust Corp increased its stake in GH Research by 26.8% in the 4th quarter. Northern Trust Corp now owns 40,834 shares of the company's stock worth $286,000 after buying an additional 8,641 shares during the period. Finally, Two Sigma Investments LP purchased a new position in GH Research in the 4th quarter worth about $117,000. Institutional investors own 56.90% of the company's stock.

GH Research Company Profile

GH Research PLC, together with its subsidiary GH Research Ireland Limited, engages in developing various therapies to treat psychiatric and neurological disorders. It is involved in the development of 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD).